Targeting cistrome and dysregulated transcriptome of post-MPN sAML

por Verstovsek, Srdan, Fiskus, Warren, Manshouri, Taghi, Bhalla, Kapil N.
Publicado 2017

Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer

por Venkannagari, Sreedhar, Fiskus, Warren, Peth, Karissa, Atadja, Peter, Hidalgo, Manuel, Maitra, Anirban, Bhalla, Kapil N.
Publicado 2012

EVI1 dysregulation: impact on biology and therapy of myeloid malignancies

por Birdwell, Christine, Fiskus, Warren, Kadia, Tapan M., DiNardo, Courtney D., Mill, Christopher P., Bhalla, Kapil N.
Publicado 2021

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

por Fiskus, Warren, Sharma, Sunil, Shah, Bhavin, Portier, Bryce P., Devaraj, Santhana G. T., Liu, Ka, Iyer, Swaminathan P., Bearss, David, Bhalla, Kapil N.
Publicado 2014

HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist

por Devaraj, Santhana G. T., Fiskus, Warren, Shah, Bhavin, Qi, Jun, Sun, Baohua, Iyer, Swaminathan P, Sharma, Sunil, Bradner, James E., Bhalla, Kapil N.
Publicado 2015

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells

por Fiskus, Warren, Sharma, Sunil, Saha, Saikat, Shah, Bhavin, Devaraj, Santhana G. T., Sun, Baohua, Horrigan, Stephen, Leveque, Christopher, Zu, Youli, Iyer, Swaminathan, Bhalla, Kapil N.
Publicado 2014

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

por Ha, Kyungsoo, Fiskus, Warren, Choi, Dong Soon, Bhaskara, Srividya, Cerchietti, Leandro, Devaraj, Santhana G. T., Shah, Bhavin, Sharma, Sunil, Chang, Jenny C., Melnick, Ari M., Hiebert, Scott, Bhalla, Kapil N.
Publicado 2014

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells

por Fiskus, Warren, Manshouri, Taghi, Birdwell, Christine, Mill, Christopher P., Masarova, Lucia, Bose, Prithviraj, Kadia, Tapan M., Daver, Naval, DiNardo, Courtney D., Borthakur, Gautam, Khoury, Joseph D., Verstovsek, Srdan, Bhalla, Kapil N.
Publicado 2022

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

por Saenz, Dyana T., Fiskus, Warren, Manshouri, Taghi, Rajapakshe, Kimal, Krieger, Stephanie, Sun, Baohua, Mill, Christopher P., DiNardo, Courtney, Pemmaraju, Naveen, Kadia, Tapan, Parmar, Simrit, Sharma, Sunil, Coarfa, Cristian, Qiu, Peng, Verstovsek, Srdan, Bhalla, Kapil N.
Publicado 2016

SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of cMYC oncoprotein

por Geng, Chuandong, Kaochar, Salma, Li, Min, Rajapakshe, Kimal, Fiskus, Warren, Dong, Jianrong, Foley, Christopher, Dong, Boming, Zhang, Li, Kwon, Oh-Joon, Shah, Shrijal S., Bolaki, Menaka, Xin, Li, Ittmann, Michael, O’Malley, Bert W., Coarfa, Cristian, Mitsiades, Nicholas
Publicado 2017

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1

por Mill, Christopher P., Fiskus, Warren, Das, Kaberi, Davis, John A., Birdwell, Christine E., Kadia, Tapan M., DiNardo, Courtney D., Daver, Naval, Takahashi, Koichi, Sasaki, Koji, McGeehan, Gerard M., Ruan, Xinjia, Su, Xiaoping, Loghavi, Sanam, Kantarjian, Hagop, Bhalla, Kapil N.
Publicado 2023

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

por Fiskus, Warren, Daver, Naval, Boettcher, Steffen, Mill, Christopher P., Sasaki, Koji, Birdwell, Christine E., Davis, John A., Das, Kaberi, Takahashi, Koichi, Kadia, Tapan M., DiNardo, Courtney D., Burrows, Francis, Loghavi, Sanam, Khoury, Joseph D., Ebert, Benjamin L., Bhalla, Kapil N.
Publicado 2022

BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma

por Fiskus, Warren, Mill, Christopher P., Perera, Dimuthu, Birdwell, Christine, Deng, Qing, Yang, Haopeng, Lara, Bernardo H., Jain, Nitin, Burger, Jan, Ferrajoli, Alessandra, Davis, John A., Saenz, Dyana T., Jin, Wendy, Coarfa, Cristian, Crews, Craig M., Green, Michael R., Khoury, Joseph D., Bhalla, Kapil N.
Publicado 2021

Inhibition of GATA2 in prostate cancer by a clinically available small molecule

por Kaochar, Salma, Rusin, Aleksandra, Foley, Christopher, Rajapakshe, Kimal, Robertson, Matthew, Skapura, Darlene, Mason, Cammy, Berman De Ruiz, Karen, Tyryshkin, Alexey Mikhailovich, Deng, Jenny, Shin, Jin Na, Fiskus, Warren, Dong, Jianrong, Huang, Shixia, Navone, Nora M, Davis, Christel M, Ehli, Erik A, Coarfa, Cristian, Mitsiades, Nicholas
Publicado 2021

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

por Fiskus, Warren, Boettcher, Steffen, Daver, Naval, Mill, Christopher P., Sasaki, Koji, Birdwell, Christine E., Davis, John A., Takahashi, Koichi, Kadia, Tapan M., DiNardo, Courtney D., Jin, Qi, Qi, Yuan, Su, Xiaoping, McGeehan, Gerard M., Khoury, Joseph D., Ebert, Benjamin L., Bhalla, Kapil N.
Publicado 2022

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

por Fiskus, Warren, Mill, Christopher P., Birdwell, Christine, Davis, John A., Das, Kaberi, Boettcher, Steffen, Kadia, Tapan M., DiNardo, Courtney D., Takahashi, Koichi, Loghavi, Sanam, Soth, Michael J., Heffernan, Tim, McGeehan, Gerard M., Ruan, Xinjia, Su, Xiaoping, Vakoc, Christopher R., Daver, Naval, Bhalla, Kapil N.
Publicado 2023

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

por Fiskus, Warren, Cai, Tianyu, DiNardo, Courtney D., Kornblau, Steven M., Borthakur, Gautam, Kadia, Tapan M., Pemmaraju, Naveen, Bose, Prithviraj, Masarova, Lucia, Rajapakshe, Kimal, Perera, Dimuthu, Coarfa, Cristian, Mill, Christopher P., Saenz, Dyana T., Saenz, David N., Sun, Baohua, Khoury, Joseph D., Shen, Yu, Konopleva, Marina, Bhalla, Kapil N.
Publicado 2019

Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Second...

por Saenz, Dyana T., Fiskus, Warren, Qian, Yimin, Manshouri, Taghi, Rajapakshe, Kimal, Raina, Kanak, Coleman, Kevin G., Crew, Andrew P., Shen, Angela, Mill, Christopher P., Sun, Baohua, Qiu, Peng, Kadia, Tapan M., Pemmaraju, Naveen, DiNardo, Courtney, Kim, Mi-Sun, Nowak, Agnieszka J., Coarfa, Cristian, Crews, Craig M., Verstovsek, Srdan, Bhalla, Kapil N.
Publicado 2017

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells

por Fiskus, Warren, Mill, Christopher P., Nabet, Behnam, Perera, Dimuthu, Birdwell, Christine, Manshouri, Taghi, Lara, Bernardo, Kadia, Tapan M., DiNardo, Courtney, Takahashi, Koichi, Daver, Naval, Bose, Prithviraj, Masarova, Lucia, Pemmaraju, Naveen, Kornblau, Steven, Borthakur, Gautam, Montalban-Bravo, Guillermo, Manero, Guillermo Garcia, Sharma, Sunil, Stubbs, Matthew, Su, Xiaoping, Green, Michael R., Coarfa, Cristian, Verstovsek, Srdan, Khoury, Joseph D., Vakoc, Christopher R., Bhalla, Kapil N.
Publicado 2021